Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the ESPGHAN hepatology committee

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 5, 2012, Pages 700-713

  Vajro, Pietro ^a   Lenta, Selvaggia ^b   Socha, Piotr ^c   Dhawan, Anil ^d   McKiernan, Patrick ^e   Baumann, Ulrich ^f   Durmaz, Ozlem ^g   Lacaille, Florence ^h   McLin, Valerie ⁱ   Nobili, Valerio ^j  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

children; histology; imaging; liver biopsy; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; noninvasive biomarkers; obesity related liver disease

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALANINE AMINOTRANSFERASE; ALCOHOL; AMIODARONE; APOLIPOPROTEIN A1; ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; COCAINE; CORTICOSTEROID; DILTIAZEM; ESTROGEN; GLUCOSE; GLUCURONOSYLTRANSFERASE 1A1; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 6; METHOTREXATE; NIFEDIPINE; PERHEXILINE; PESTICIDE; PREDNISOLONE; TAMOXIFEN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALPROIC ACID; VITAMIN; ZIDOVUDINE;

ABDOMINAL PAIN; ACANTHOSIS NIGRICANS; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECHOGRAPHY; ELASTOGRAPHY; END STAGE LIVER DISEASE; FATIGUE; GLUCOSE BLOOD LEVEL; HEPATITIS; HEPATOMEGALY; HISPANIC; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER TOXICITY; LOW BIRTH WEIGHT; MALAISE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; CHILD; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GASTROENTEROLOGY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; OBESITY; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 84859970076     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318252a13f     Document Type: Article

References (127)

1. Loomba R, Sirlin CB, Schwimmer JB, et al. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009;50:1282-93.
2. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93. (Pubitemid 46393782)
3. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-44.
4. Molleston JP, White F, Teckman J, et al. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002;97:2460-2.
5. Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-96.
6. Kistler KD, Molleston J, Unlap A, et al. Symptoms and quality of life in obese children and adolescents with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2010;31:396-406.
7. Socha P,Wierzbicka A, Dhawan A. Non alcoholic fatty liver disease in children. In: Jara P, ed. International Hepatology Updates: Liver Diseases in Children. Barcelona, Spain: Perlmayer; 2009:147-161.
8. De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int 2010;4:375-85.
9. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007;46:582-9. (Pubitemid 47344794)
10. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 7:1898-906. (Pubitemid 40824701)
11. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-74. (Pubitemid 41233660)
12. Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 4:1281-90.
13. Romeo S, Sentinelli F, Cambuli VM, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010;53:335-8.
14. Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010;4:1274-80.
15. Carulli L, Canedi I, Rondinella S, et al. Genetic polymorphisms in nonalcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis 2009; 41:823-8.
16. Tokushige K, Takakura M, Tsuchiya-Matsushita N, et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 2007;46:1104-10. (Pubitemid 46669735)
17. Miele L, Beale G, Patman G, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008;135:282-91.
18. Lin YC, Chang PF, Hu FC, et al. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 2009; 124:e1221-7.
19. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a ''growing'' problem? J Hepatol 2007;46:1133-42. (Pubitemid 46680362)
20. Cassiman D, Jaeken J. NASH may be trash. Gut 2008;57:141-4. (Pubitemid 351158033)
21. Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003;143:500-5. (Pubitemid 37352510)
22. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-9. (Pubitemid 41233657)
23. Louthan MV, Theriot JA, Zimmerman E, et al. Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterol Nutr 2005;4:426-9. (Pubitemid 41407604)
24. Willner IR,Waters B, Patil SR, et al. Ninety patients with non alcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61. (Pubitemid 32959539)
25. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of non alcoholic fatty liver disease. Gastroenterology 2009;136:1585-92.
26. Patton HM, Lavine JE, Van Natta ML, et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008;135:1961-71.
27. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42:1428-32. (Pubitemid 27339358)
28. Nobili V, Alisi A, Panera N, et al. Low birth weight and catch-upgrowth associated with metabolic syndrome: a ten year systematic review. Pediatr Endocrinol Rev 2008;6:241-7.
29. Nobili V, Bedogni G, Alisi A, et al. A protective effect of breastfeeding on the progression of NAFLD. Arch Dis Child 2009;94:801-5.
30. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1961-71.
31. Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol 2010; 16:4243-52.
32. Mandato C, Lucariello S, Licenziati MR, et al. Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease. J Pediatr 2005;147:62-6. (Pubitemid 40981147)
33. Taylor RW, Jones IE, Williams SM, et al. Evaluation of waist circumference, waist-to-hip ratio, and the conicity index as screening tools for high trunk fat mass, as measured by dual-energy X-ray absorptiometry, in children aged 3-19 y. Am J Clin Nutr 2000; 72:490-5. (Pubitemid 30620657)
34. Moreno LA, Pineda I, Rodr?́guez G, et al. Waist circumference for the screening of the metabolic syndrome in children. Acta Paediatr 2002;91:1307-12. (Pubitemid 36174054)
35. McCarthy HD, Jarrett KV, Crawley HF. The development of waist circumference percentiles in British children aged 5.0-16.9 years. Eur J Clin Nutr 2001;55:902-7. (Pubitemid 32927057)
36. Katzmarzyk PT. Waist circumference percentiles for Canadian youth 11-18 y of age. Eur J Clin Nutr 2004;58:1011-5. (Pubitemid 39077146)
37. Lin YC, Chang PF, Yeh SJ, et al. Risk factors for liver steatosis in obese children and adolescents. Pediatr Neonatol 2010;51:149-54.
38. Manco M, Bedogni G, Marcellini M, et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut 2008;9:1283-7.
39. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994;125:239-41. (Pubitemid 24253007)
40. Nobili V, Reale A, Alisi A, et al. Elevated serum ALT in children presenting to the emergency unit: relationship with NAFLD. Dig Liver Dis 2009;41:749-52.
41. Manco M, Alisi A, Nobili V. Risk of severe liver disease in NAFLD with normal ALT levels: a pediatric report. Hepatology 2008; 48:2087-8.
42. Burgert TS, Taksali SE, Dziura J, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006;91:4287-94. (Pubitemid 44833400)
43. Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010;138:1357-64.
44. England K, Thorne C, Pembrey L, et al. Age- and sex-related reference ranges of alanine aminotransferase levels in children: European Paediatric HCV Network. J Pediatr Gastroenterol Nutr 2009;49:71-7.
45. Fishbein MH, Miner M, Mogren C, et al. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003;36:54-61. (Pubitemid 41672620)
46. Tahan V, Canbakan B, Balci H, et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 2008;55:1433-8.
47. Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009; 21:529-35.
48. Cambuli VM, Incani M, Pilia S, et al. Oral glucose tolerance test in Italian overweight/obese children and adolescents results in a very high prevalence of impaired fasting glycaemia, but not of diabetes. Diabetes Metab Res Rev 2009;25:528-34.
49. Sartorio A, Del Col A, Agosti F, et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007;61:877-83. (Pubitemid 47040311)
50. Oliveira AM, Oliveira N, Reis JC, et al. Triglycerides and alanine aminotransferase as screening markers for suspected fatty liver disease in obese children and adolescents. Horm Res 2009;71:83-8.
51. Engiz O, Berberog?lu M, Siklar Z, et al. Risk factors for non-alcoholic fatty liver disease in obese children. Horm Res 2009;72:63-4.
52. Nobili V, Alkhouri N, Bartuli A, et al. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res 2010;67:665-70.
53. Lonardo A, Loria P, Leonardi F, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002;34:204-11. (Pubitemid 34269566)
54. Germenis AE, Yiannaki EE, Zachou K, et al. Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. Clin Diagn Lab Immunol 2005;12:941-8.
55. Franzese A, Iannucci MP, Valerio G, et al. Atypical celiac disease presenting as obesity-related liver dysfunction. J Pediatr Gastroenterol Nutr 2001;33:329-32. (Pubitemid 32947339)
56. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004;99:1316-20. (Pubitemid 39062269)
57. Veropalumbo C, Del Giudice E, Capuano G, et al. Duchenne and Becker muscular dystrophy presenting as nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011;53:463-4.
58. Spindelboeck W, Deutschmann A, Lackner K, et al. Obesity and Wilson disease in childhood and adolescence. J Pediatr Gastroenterol Nutr 2009;48(suppl 3):E63.
59. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
60. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203.
61. Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809-20.
62. Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006;44:458-65. (Pubitemid 44214885)
63. Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009;48:1113-20.
64. Vuppalanchi R, Unalp A, Van Natta M, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 4:481-6.
65. Pietrobattista A, Fruwirth R, Natali G, et al. Is juvenile liver biopsy unsafe? Putting an end to a common misapprehension. Pediatr Radiol 2009;39:959-61.
66. Harwood J, Bishop P, Liu H, et al. Safety of blind percutaneous liver biopsy in obese children: a retrospective analysis. J Clin Gastroenterol 2010;44:e253-5.
67. Manco M, Bottazzo G, DeVito R, et al. Nonalcoholic fatty liver disease in children. J Am Coll Nutr 2008;27:667-76.
68. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
69. Roldan-Valadez E, Favila R, Mart?́nez-López M, et al. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 2008;7:212-20.
70. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric non alcoholic steatohepatitis. Hepatology 2008;48:442-8.
71. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26-31.
72. Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009;51:1061-7.
73. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-50. (Pubitemid 34977081)
74. Shannon A, Alkhouri N, Carter-Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr 2011;53:190-5.
75. Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485-9. (Pubitemid 44356237)
76. Mancini M, Prinster A, Annuzzi G, et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with [1]H magnetic resonance spectroscopy. Metabolism 2009;58:1724-30.
77. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011;52:740-3.
78. Park Sh, Kim Pn, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-12.
79. Radetti G, Kleon W, Stuefer J, et al. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr 2006;95:833-7. (Pubitemid 44261742)
80. Pacifico L, Celestre M, Anania C, et al. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 2007;96:542-7. (Pubitemid 46466114)
81. Kim SH, Lee JM, Han JK, et al. Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging-correlation with histopathologic findings. Radiology 2006;240:116-29. (Pubitemid 43902601)
82. Pozzato C, Verduci E, Scaglioni S, et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. J Pediatr Gastroenterol Nutr 2010;51:331-5.
83. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011;5:740-3.
84. Kim H, Taksali SE, Dufour S, et al. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL. Magn Reson Med 2008; 59:521-7. (Pubitemid 351348223)
85. Schwimmer JB, Middleton MS, Deutsch R, et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2005;21:871-9. (Pubitemid 40477247)
86. Bohte AE, van Werven JR, Bipat S, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011;21: 87-97.
87. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-50. (Pubitemid 40439195)
88. de Lédinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45:443-50. (Pubitemid 350307163)
89. Fukuzawa Y, Ohashi T, Matsumoto EJ, et al. Efficacy of non-invasive hepatic fibrosis quantification by liver elasticity measurement in NASH-comparison of ultrasonic transient elastography and histopathological diagnosis. Gastroenterology 2006;130:A-79 [abstract].
90. Francavilla R, Cecinati V, Castellaneta S, et al. Normal values of transient elastography (fibroscan) in children without evidence of liver disease: comparison of adult versus pediatric probe. Dig Liver Dis 2009;41S3:202-3 [abstract].
91. Gulizia R, Ferraioli G, Filice C. Open questions in the assessment of liver fibrosis using real-time elastography. Am J Roentgenol 2008;190:W370-1. (Pubitemid 351798562)
92. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine- adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-45. (Pubitemid 44307061)
93. Lebensztejn DM, Wojtkowska M, Skiba E, et al. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci 2009;54:177-82.
94. Nobili V, Manco M, Ciampalini P, et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol 2006;155:735-43. (Pubitemid 44857498)
95. Manco M, Marcellini M, Giannone G, et al. Correlation of serum TNFalpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 2007;127:954-60.
96. Nobili V, Alkhouri N, Alisi A, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric non alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:575-9.
97. Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010;50:645-9.
98. Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007;42:573-82. (Pubitemid 47190075)
99. Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006;4:918-23.
100. Nelson JE, Bhattacharya R, Lindor KD, et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in caucasians with nonalcoholic steatohepatitis. Hepatology 2007;46:723-9. (Pubitemid 47436118)
101. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 2008;93:4479-85. (Pubitemid 352789550)
102. Bonnefonnt-Rousselot D, Ratziu V, Giral P, et al. Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment Pharmacol Ther 2006;23:91-8. (Pubitemid 43381171)
103. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-502. (Pubitemid 39193189)
104. Bell LN, Molleston JP, Morton MJ, et al. Hepatic lipid peroxidation and cytochrome p-450 2e1 in pediatric nonalcoholic fatty liver disease and its subtypes. J Clin Gastroenterol 2011;45:800-7.
105. Piemonte F, Petrini S, Gaeta LM, et al. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2008;23:e457-64.
106. Nobili V, Parola M, Alisi A, et al. Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. Int J Mol Med 2010; 26:471-6.
107. Yilmaz J, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of metabolic syndrome in non alcoholic steatohepatitis. World J Gastroenterol 2009;15:4387-91.
108. Vos MB, Barve S, Joshi-Barve S, et al. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008;47:481-5.
109. Fitzpatrick E, Mitry RR, Quaglia A, et al. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 2010;51:500-6.
110. Calès P, Lainé F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009;50:165-73.
111. Vizzutti F, Arena U, Nobili V. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8:89-94.
112. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (Fibro Test-Fibro SURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:1-14.
113. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with non alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104-12.
114. Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med 2009;7:21.
115. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009;136:160-7.
116. Alkhouri N, Carter-Kent C, Lopez R, et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol 2011; 9:150-5.
117. Vajro P, De Chiara C, D'Armiento M, et al. Serum hyaluronic acid and laminin in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 1994;6:1023-6. (Pubitemid 24322873)
118. Nobili V, Alisi A, Torre G, et al. Hyaluronic acid predicts hepatic fibrosis in children with non-alcoholic fatty liver disease. Transl Res 2010;156:229-34.
119. Miele L, Forgione A, La Torre G, et al. Serum levels of hyaluronic acid and tissue inhibitor of metalloproteinase-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res 2009; 154:194-201.
120. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:10.
121. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholosteato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:1-16.
122. Munteanu M, Ratziu V, Morra R, et al. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointest Liver Dis 2008;17:187-91. (Pubitemid 351930766)
123. Trak-Smayra V, Dargere D, Noun R, et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009;58:825-32.
124. Bell LN, Theodorakis JL, Vuppalanchi R, et al. Serum proteomics and biomarker discovery across the spectrum of non-alcoholic fatty liver disease. Hepatology 2010;51:111-20.
125. Loria P, Adinolfi LE, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;4:272-82.
126. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;2:372-84.
127. Vajro P, Veropalumbo C. Citrin deficiency: learn more and don't forget to add it to the list of neonatal cholestasis and the NASH trash bin. J Pediatr Gastroenterol Nutr 2010;50:578-9.